Advertisement

Advertisement

HRTX Stock Latest News

Heron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward

RatingsHeron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward

Heron Therapeutics Strengthens Executive Contracts Amid Strategic Focus

PremiumCompany Announcements

Heron Therapeutics Strengthens Executive Contracts Amid Strategic Focus

29d ago

Heron Therapeutics Signals Profitable Growth After Strong Quarter

PremiumCompany Announcements

Heron Therapeutics Signals Profitable Growth After Strong Quarter

2M ago

Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target

PremiumRatings

Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target

2M ago

Heron Therapeutics reports Q4 EPS (2c) vs 2c last year

PremiumThe Fly

Heron Therapeutics reports Q4 EPS (2c) vs 2c last year

2M ago

Heron Therapeutics sees FY26 revenue $173M-$183M

PremiumThe FlyHeron Therapeutics sees FY26 revenue $173M-$183M

2M ago

HRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Pre-Earnings

HRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

2M ago

Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum

Ratings

Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum

4M ago

Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue

PremiumCompany Announcements

Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue

4M ago

Heron Therapeutics: ZYNRELEF-Led Commercial Inflection and Undemanding Valuation Support Buy Rating and $6 Target

PremiumRatings

Heron Therapeutics: ZYNRELEF-Led Commercial Inflection and Undemanding Valuation Support Buy Rating and $6 Target

4M ago

Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

PremiumThe Fly

Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

4M ago

Roth Capital healthcare analyst holds an analyst/industry conference call

PremiumThe Fly

Roth Capital healthcare analyst holds an analyst/industry conference call

5M ago

Heron Therapeutics announces APONVIE inclusion in PONV guidelines

PremiumThe FlyHeron Therapeutics announces APONVIE inclusion in PONV guidelines

5M ago

Heron Therapeutics Reports Strong Q3 2025 Revenue Growth

Company Announcements

Heron Therapeutics Reports Strong Q3 2025 Revenue Growth

6M ago

Heron Therapeutics’ Earnings Call: Growth Amid Challenges

Company Announcements

Heron Therapeutics’ Earnings Call: Growth Amid Challenges

6M ago

Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth

PremiumRatings

Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth

6M ago

Heron Therapeutics price target lowered to $5 from $6 at Jefferies

PremiumThe Fly

Heron Therapeutics price target lowered to $5 from $6 at Jefferies

6M ago

Heron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market Potential

PremiumRatings

Heron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market Potential

6M ago

Promising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics

PremiumRatings

Promising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics

6M ago

Heron Therapeutics reports Q3 EPS (10c), consensus (1c)

PremiumThe FlyHeron Therapeutics reports Q3 EPS (10c), consensus (1c)

6M ago

Heron Therapeutics sees FY25 revenue $153M-$163M, consensus $156.48M

The Fly

Heron Therapeutics sees FY25 revenue $153M-$163M, consensus $156.48M

6M ago

HRTX Upcoming Earnings Report: What to Expect?

Pre-Earnings

HRTX Upcoming Earnings Report: What to Expect?

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >